Seres Therapeutics (NASDAQ:MCRB) Shares Pass Above 50 Day Moving Average - Should You Sell?

Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $8.27 and traded as high as $12.18. Seres Therapeutics shares last traded at $11.36, with a volume of 107,170 shares changing hands.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on MCRB shares. Chardan Capital reaffirmed a "neutral" rating and set a $6.00 target price (up previously from $1.25) on shares of Seres Therapeutics in a research report on Thursday, May 8th. The Goldman Sachs Group dropped their target price on Seres Therapeutics from $20.00 to $15.00 and set a "sell" rating on the stock in a research report on Friday, March 14th. Finally, Wall Street Zen raised Seres Therapeutics from a "sell" rating to a "hold" rating in a research report on Friday, May 9th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $73.67.

Seres Therapeutics Trading Down 8.6%

The stock has a market cap of $94.72 million, a price-to-earnings ratio of -2.36 and a beta of 2.75. The stock has a 50-day moving average price of $8.30 and a two-hundred day moving average price of $12.43.

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported ($2.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.67) by ($1.57). Research analysts predict that Seres Therapeutics, Inc. will post -0.38 earnings per share for the current fiscal year.

Institutional Trading of Seres Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. lifted its position in Seres Therapeutics by 40.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company's stock worth $52,000 after acquiring an additional 21,679 shares during the period. Invesco Ltd. lifted its position in Seres Therapeutics by 193.2% during the 1st quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company's stock worth $96,000 after acquiring an additional 89,995 shares during the period. SBI Securities Co. Ltd. lifted its position in Seres Therapeutics by 221.8% during the 1st quarter. SBI Securities Co. Ltd. now owns 69,664 shares of the biotechnology company's stock worth $49,000 after acquiring an additional 48,013 shares during the period. Vontobel Holding Ltd. lifted its position in Seres Therapeutics by 15.7% during the 1st quarter. Vontobel Holding Ltd. now owns 1,085,966 shares of the biotechnology company's stock worth $760,000 after acquiring an additional 147,671 shares during the period. Finally, Millennium Management LLC lifted its position in Seres Therapeutics by 77.2% during the 4th quarter. Millennium Management LLC now owns 1,810,719 shares of the biotechnology company's stock worth $1,505,000 after acquiring an additional 788,762 shares during the period. Institutional investors and hedge funds own 59.34% of the company's stock.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.